N-(2-(5-chloro-1H-indol-3-yl)ethyl)-1-(1-methyl-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide | 1258502-56-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-(5-chloro-1H-indol-3-yl)ethyl)-1-(1-methyl-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide
• 英文别名: N-[2-(5-chloro-1H-indol-3-yl)ethyl]-1-(1-methylpyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide
• CAS: 1258502-56-5
• 化学式: C₁₉H₂₀ClN₅O₂
• 分子量: 385.853
• InChiKey: NQCMJHZXHNGCMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-氯-1H-吲哚-3-乙胺盐酸盐 、 1-(1-methyl-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxylic acid 1-(1-methyl-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxylic acid 、 1H-苯并三唑-1-基氧三吡咯烷基六氟磷酸盐 、 N,N-二异丙基乙胺 在 crude mixture 、 silica 、 eluent 、 乙酸乙酯 、 正庚烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以to yield 0.015 g (13%) of N-(2-(5-chloro-1H-indol-3-yl)ethyl)-1-(1-methyl-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide as a white solid的产率得到N-(2-(5-chloro-1H-indol-3-yl)ethyl)-1-(1-methyl-1H-pyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide
  参考文献：
  名称：

  Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases

  摘要：

  本发明提供了新型化合物及其作为药物的应用，更具体地用于预防或治疗神经退行性疾病，更进一步地，用于治疗某些神经系统疾病，如被统称为tau病理学的疾病和由细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及使用所述新型化合物制备用于治疗此类神经退行性疾病的药物。本发明还涉及含有所述新型化合物的制药组合物以及所述新型化合物的制备方法。

  公开号：

  US09434722B2

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• [EN] INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS<br/>[FR] INHIBITEURS DE PDE6DELTA DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION ET/OU LE TRAITEMENT DE L'ÉPILEPSIE ET/OU DE TROUBLES NEURODÉGÉNÉRATIFS
  申请人：REMYND N V

  公开号：WO2018206757A1

  公开（公告）日：2018-11-15

  The present provides compounds and methods for preventing and/or treating epilepsy and/or neurodegenerative disorders. More particularly, the invention provides inhibitors of PDE6δ for use in the prevention and/or treatment of neurodegenerative disorders and/or epilepsy.

  本发明提供了用于预防和/或治疗癫痫和/或神经退行性疾病的化合物和方法。更具体地说，该发明提供了用于预防和/或治疗神经退行性疾病和/或癫痫的PDE6δ抑制剂。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。
• INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS
  申请人：Remynd N.V.

  公开号：EP3634407A1

  公开（公告）日：2020-04-15
• Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases
  申请人：Katholieke Universiteit Leuven, K.U. Leuven R&D

  公开号：US20190054068A1

  公开（公告）日：2019-02-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.